Top Line

Regeneron’s antibody cocktail reduces risk of contracting COVID-19 for up to eight months, company announced Monday, potentially paving the way for regulators to green the product as a deterrent and offering hope for immunocompromised people and those not responding to vaccination.

important facts

- Advertisement -

The New York-based biotech said a single dose of Regeneron’s antibody cocktail—administered via four injections—reduced the risk of contracting COVID-19 by 81.6% for up to eight months.

The study, which was conducted by the company and has not yet been published or peer-reviewed, makes On earlier work demonstrating the treatment to reduce the risk of contracting COVID-19 by 81% in the first month after administration.

Regeneron Chief Scientific Officer George Yankopoulos said the data adds to a growing body of evidence supporting the use of antibody cocktails to prevent COVID-19, a boon for immunocompromised people who remain “prisoners of the pandemic”. , who are vulnerable despite infection. Vaccination.

Yancopoulos said the company plans to “rapidly” share the additional data with regulators, which could pave the way for the Food and Drug Administration (FDA) to approve the treatment for additional uses.

While the FDA has granted the antibody cocktail emergency use authorization to treat outpatients at risk of serious illness or to prevent disease in at-risk groups exposed to the virus, it is also intended to prevent infection in those who have been exposed to the virus. Not approved, those are already known. Exposure prophylaxis (PrEP).

- Advertisement -